Tumor-associated macrophages correlate with progesterone receptor loss in endometrial endometrioid adenocarcinoma

Journal of Obstetrics and Gynaecology Research

Volumn 39, Issue 4, 2013, Pages 855-863

  Jiang, Xue Feng ^a   Tang, Qiong Lan ^b   Li, Hai Gang ^b   Shen, Xi Ming ^b   Luo, Xin ^a   Wang, Xiao Yu ^a   Lin, Zhong Qiu ^b  

^a THE FIRST AFFILIATED HOSPITAL OF JINAN UNIVERSITY   (China)

^b SUN YAT SEN MEMORIAL HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

CD68; Endometrial endometrioid adenocarcinoma; Progesterone receptor; Tumor associated macrophages

Indexed keywords

CD34 ANTIGEN; CD68 ANTIGEN; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; VASCULOTROPIN;

ADULT; ARTICLE; CANCER PROGNOSIS; CELL COUNT; DISEASE COURSE; DISEASE SEVERITY; ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; SURVIVAL RATE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR INVASION;

ADENOCARCINOMA; ADULT; AGED; CARCINOMA, ENDOMETRIOID; COHORT STUDIES; DOWN-REGULATION; ENDOMETRIAL HYPERPLASIA; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEMALE; FOLLOW-UP STUDIES; HUMANS; MACROPHAGES; MIDDLE AGED; NEOPLASM PROTEINS; PRECANCEROUS CONDITIONS; RECEPTORS, PROGESTERONE; SURVIVAL ANALYSIS;

EID: 84880000091     PISSN: 13418076     EISSN: 14470756     Source Type: Journal    
DOI: 10.1111/j.1447-0756.2012.02036.x     Document Type: Article

References (27)

1. De Visser KE, Coussens LM. The inflammatory tumor microenvironment and its impact on cancer development. Contrib Microbiol 2006; 13: 118-137.
2. Mantovani A. Cancer: Inflammation by remote control. Nature 2005; 435: 752-753.
3. Hammes LS, Tekmal RR, Naud P et al. Macrophages, inflammation and risk of cervical intraepithelial neoplasia (CIN) progression - clinicopathological correlation. Gynecol Oncol 2007; 105: 157-165.
4. Ohno S, Ohno Y, Suzuki N. Correlation of histological localization of tumor-associated macrophages with clinicopathological features in endometrial cancer. Anticancer Res 2004; 45: 3335-3342.
5. Tanaka Y, Kobayashi H, Suzuki M et al. Thymidine phosphorylase expression in tumor-infiltrating macrophages may be correlated with poor prognosis in uterine endometrial cancer. Hum Pathol 2002; 33: 1105-1113.
6. Fujimoto J, Aoki I, Toyoki H et al. Clinical implications of expression of interleukin-8 related to myometrial invasion with angiogenesis in uterine endometrial cancers. Ann Oncol 2002; 13: 430-434.
7. Hashimoto I, Kodama J, Seki N. Macrophage infiltration and angiogenesis in endometrial cancer. Anticancer Res 2000; 20: 4853-4856.
8. Espinosa I, José Carnicer M, Catasus L et al. Myometrial invasion and lymph node metastasis in endometrioid carcinomas: Tumor-associated macrophages, microvessel density, and HIF1A have a crucial role. Am J Surg Pathol 2010; 34: 1708-1714.
9. Soeda S, Nakamura N, Ozeki T et al. Tumor-associated macrophages correlate with vascular space invasion and myometrial invasion in endometrial carcinoma. Gynecol Oncol 2008; 109: 122-128.
10. Creasman W. Revised FIGO staging for carcinoma of the endometrium. Int J Gynaecol Obstet 2009; 105: 109.
11. Weidner N. Intratumor microvessel density as a prognostic factor in cancer. Am J Pathol 1995; 147: 9-19.
12. Zhou ZQ, Cao WH, Xie JJ et al. Expression and prognostic significance of THBS1, Cyr61 and CTGF in esophageal squamous cell carcinoma. BMC Cancer 2009; 9: 291-298.
13. Sherman ME. Theories of endometrial carcinogenesis: A multidisciplinary approach. Mod Pathol 2000; 13: 295-308.
14. Tang Q, Jiang X, Li H et al. Expression and prognostic value of WISP-1 in patients with endometrial endometrioid adenocarcinoma. J Obstet Gynaecol Res 2011; 37: 606-612.
15. Modugno F, Ness RB, Chen C et al. Inflammation and endometrial cancer: A hypothesis. Cancer Epidemiol Biomarkers Prev 2005; 14: 2840-2487.
16. Pikarsky E, Porat RM, Stein I et al. NF-kB functions as a tumour promoter in inflammation-associated cancer. Nature 2004; 431: 461-466.
17. Purohit A, Newman SP, Reed MJ. The role of cytokines in regulating estrogen synthesis: Implications for the etiology of breast cancer. Breast Cancer Res 2002; 4: 65-69.
18. Macdiarmid F, Wang D, Duncan LJ et al. Stimulation of aromatase activity in breast fibroblasts by tumor necrosis factor alpha. Mol Cell Endocrinol 1994; 106: 17-21.
19. Van der Horst PH, Wang Y, Vandenput I et al. Progesterone inhibits epithelial-to-mesenchymal transition in endometrial cancer. PLoS ONE 2012; 7: e30840.
20. Wang Y, Hanifi-Moghaddam P, Hanekamp EE et al. Progesterone inhibition of Wnt/beta-catenin signaling in normal endometrium and endometrial cancer. Clin Cancer Res 2009; 15: 5784-5793.
21. Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science 2011; 331: 1559-1564.
22. Kalluri R,Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009; 119: 1420-1428.
23. Ramirez PT, Frumovitz M, Bodurka DC et al. Hormonal therapy for the management of grade 1 endometrial adenocarcinoma: A literature review. Gynecol Oncol 2004; 95: 133-138.
24. Ehrlich CE, Young PC, Stehman FB et al. Steroid receptors and clinical outcome in patients with adenocarcinoma of the endometrium. Am J Obstet Gynecol 1988; 158: 796-807.
25. Kim YB, Berek JS, Martinez-Maza O et al. Vascular endothelial growth factor expression is not regulated by estradiol or medroxyprogesterone acetate in endometrial carcinoma. Gynecol Oncol 1996; 61: 97-100.
26. Mueller MD, Vigne JL, Pritts EA et al. Progestins activate vascular endothelial growth factor gene transcription in endometrial adenocarcinoma cells. Fertil Steril 2003; 79: 386-392.
27. Creasman WT. Prognostic significance of hormone receptors in endometrial cancer. Cancer 1993; 71: 1467-1470.